SciNeuro Pharmaceuticals

About SciNeuro Pharmaceuticals

SciNeuro Pharmaceuticals is dedicated to transforming scientific discoveries into groundbreaking therapies for brain diseases, aiming to restore joy in living. The company focuses on accelerating therapeutic innovation in neuroscience to benefit people worldwide with neurological conditions.

Products & Services

SNP614:A chemically modified antisense oligonucleotide (ASO) targeting LRRK2 mRNA to reduce its levels and activities linked to Parkinson's disease, offering a disease-modifying therapy superior to current symptomatic treatments.

SNP203:A best-in-class anti-SORT1 antibody that restores extracellular Progranulin (PGRN) levels to address frontotemporal dementia (GRN-FTD) and Alzheimer's disease, with superior potency and patient-friendly delivery.

SNP234:A next-generation anti-amyloid antibody targeting toxic aggregated beta-amyloid proteins in Alzheimer's disease, aiming to slow progression of amyloid-related neurodegeneration.

SNP201:A high-affinity alpha-synuclein antibody targeting pathogenic aggregated forms for synucleinopathies like Parkinson's disease, dementia with Lewy bodies, and multiple system atrophy.

SNP318:A CNS-penetrant inhibitor of Lipoprotein-Associated Phospholipase A2 (Lp-PLA2) to repair blood-brain and blood-retinal barriers, targeting neurodegenerative diseases like Alzheimer's and macular diseases.

SNP837:A blood-brain barrier (BBB) shuttle platform to deliver therapeutic molecules into the CNS, enhancing target engagement with best-in-class efficiency and modular applicability across modalities.

SNP622:A potent antisense oligonucleotide (ASO) reducing APOE4 expression, a genetic risk factor for Alzheimer's disease, to slow disease progression with superior in vivo efficacy.

SNP210:A human autoantibody targeting disease-variant TDP-43 for amyotrophic lateral sclerosis (ALS) and certain forms of frontotemporal dementia (FTD), protecting neurons from pathology.

Specialties

Neuroscience Central Nervous System (CNS) Diseases Therapeutic Innovation for Brain Diseases Neurodegenerative Disorders Parkinson's Disease Alzheimer's Disease Frontotemporal Dementia Blood-Brain Barrier Technology

Funding History

Debug: View Raw Funding Data

#	Type	Amount Fields	Date Fields	Investors
1	RT: Equity T: - FT: Equity	A: 53000000 MR: - FA: 53 million FAN: 53000000	D: 2025-12-04 FD: 2025-12-04	2 investors
2	RT: Grant T: - FT: Grant	A: 5000000 MR: - FA: $5M FAN: 5000000	D: 2025-11-20 FD: 2025-11-20	1 investors

Equity Latest

2025-12-04

$53.0M

2 investors (Pro only)

Grant 2025-11-20

$5.0M

View 1 more funding rounds with Pro

Unlock Full Funding History

Growth Metrics

+45%

Employee Growth

YoY

3.2x

Funding Growth

Last Round

12

Markets

Operating

10K+

Customers

Active

View 3 more growth metrics with Pro

Unlock All Metrics

Mock Up

Team & Leadership

M

Min Li

CEO & Director

S

Sam Agus

Chief Medical Officer

P

Paul Stead

CBO

L

Lisa Li

Senior VP, Head of Clinical Development

J

Judith Li

Director

R

Robert Nelsen

Director

View 10 more team members with Pro

Unlock Full Team Directory

Recent News